C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study
Open Access
- 3 April 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 30 (10), 1187-1194
- https://doi.org/10.1093/eurheartj/ehp098
Abstract
The aim of the present study was to compare the prognostic value of a novel and promising marker, copeptin, with B-type natriuretic peptide (BNP), and N-terminal pro-BNP (NT-proBNP), on death or a composite cardiovascular endpoint in patients who developed heart failure after an acute myocardial infarction (AMI). From a subset of 224 patients of the OPTIMAAL study, blood samples were drawn at a mean of 3 days after AMI when all patients had signs and/or symptoms of heart failure or a left ventricular ejection fraction P < 0.01). In a multivariable Cox proportional hazards model, including all three biomarkers and other relevant covariates, a doubling of copeptin was related to a 1.83 (1.26–2.64) times increased risk of mortality (P < 0.0001) and a 1.35 (1.05–1.72) times increased risk of the composite cardiovascular endpoint (P = 0.018). Receiver operating characteristic curves indicated that copeptin [area under curve (AUC) 0.81] was a stronger predictor of mortality compared with both BNP (AUC 0.66; P = 0.0063 vs. copeptin) and NT-proBNP (AUC 0.67; P = 0.0016 vs. copeptin). Finally, changes of copeptin levels after 1 month significantly added prognostic information to the baseline value. Copeptin is a strong and novel marker for mortality and morbidity in patients with heart failure after AMI. In this population, the predictive value of copeptin was even stronger than BNP and NT-proBNP.This publication has 27 references indexed in Scilit:
- Vasopressin and Vasopressin Receptor Antagonists in Heart FailureCardiology in Review, 2009
- Assay for the Measurement of Copeptin, a Stable Peptide Derived from the Precursor of VasopressinClinical Chemistry, 2006
- Vasopressin Antagonism in Heart FailureJournal of the American College of Cardiology, 2005
- Neurohormonal Activation in Congestive Heart Failure and the Role of VasopressinThe American Journal of Cardiology, 2005
- Vasopressin: a new target for the treatment of heart failureAmerican Heart Journal, 2003
- Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial designThe American Journal of Cardiology, 1999
- Development of a novel, N-Terminal-proBNP (NT-proBNP) assay with a low detection limitScandinavian Journal of Clinical and Laboratory Investigation, 1999
- Increased plasma arginine vasopressin levels in patients with congestive heart failureJournal of the American College of Cardiology, 1983
- Radioimmunoassay of Plasma Arginine Vasopressin in Hyponatremic Patients with Congestive Heart FailureThe New England Journal of Medicine, 1981